赛升药业 reported revenue of ¥0.18B for the period ended 2026-06-30, -8.2% year on year. Net income was ¥-0.15B, a -80.7% net margin on a 67.8% gross margin. The largest revenue line is 心脑血管用药 at 45% of the total. Free cash flow for the period was ¥-0.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.18B | -8.2% |
| Gross profit | ¥0.12B | — |
| Operating income | ¥-0.17B | — |
| Net income | ¥-0.15B | -418.9% |
| Gross margin | 67.8% | Net margin -80.7% |
| Revenue Q/Q | -0.2% | — |
| Segment | Revenue | Share |
|---|---|---|
| 心脑血管用药 | ¥0.08B | 44.9% |
| 免疫系统用药 | ¥0.05B | 29.3% |
| 神经系统用药 | ¥0.04B | 23.7% |
| 其他药品、其他业务 | ¥0.00B | 2.2% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.06B | 32.2% |
| R&D | ¥0.03B | 16.4% |
| SG&A | ¥0.09B | 51.4% |
| Tax & other | ¥-0.03B | -14.6% |
| Item | Amount |
|---|---|
| Total assets | ¥3.36B |
| Total liabilities | ¥0.13B |
| Shareholders' equity | ¥3.23B |
| Equity / assets | 96.1% |
| Operating cash flow | ¥0.00B |
| Capital expenditure | ¥0.01B |
| Free cash flow | ¥-0.01B |
| Cash conversion (OCF / net income) | -8% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
东杰智能 ・ 蓝晓科技 ・ 恒锋工具 ・ 光智科技 ・ 华自科技 ・ 通合科技 ・ 华图山鼎 ・ 润欣科技 ・ 盛天网络 ・ 中科创达 ・ 富祥股份 ・ 高澜股份
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies